O-102 Results of a phase 2 study of the oral tyrosine kinase inhibitor (TKI): axitinib (AG-013736; AG) in combination with docetaxel (DOC) vs DOC plus placebo (PL) in first-line metastatic breast cancer (MBC)

✍ Scribed by S. Chan; A. Stopeck; A.A. Joy; S. Verma; A. Lluch; K.F. Liau; S. Kim; P. Bycott; D. Soulieres; H.S. Rugo

• Book ID: 118626059
• Publisher: Elsevier Science
• Year: 2007
• Tongue: English
• Weight: 42 KB
• Volume: 5
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(07)71792-5